Target intelligence / Profile preview

Kirsten rat sarcoma virus oncogene homolog (KRAS) - Son of Sevenless homolog 1 (SOS1) protein-protein interface (KRAS-SOS1 interface)

Target
KRAS-SOS1 interface
Molecular classification
Enzyme, Small GTPase, Guanine nucleotide exchange factor, Protein-protein interaction
01

Overview

The Kirsten rat sarcoma virus oncogene homolog (KRAS) - Son of Sevenless homolog 1 (SOS1) protein-protein interface is a critical regulatory node in the RAS/MAPK signaling pathway (UniProt: P01116, Q07889). KRAS functions as a molecular switch that cycles between an inactive GDP-bound state and an active GTP-bound state. SOS1, a guanine nucleotide exchange factor (GEF), facilitates the activation of KRAS by promoting the dissociation of GDP, allowing GTP to bind (PMID: 33067308). In many cancers, KRAS is constitutively active due to mutations, driving uncontrolled cell proliferation and survival. Targeting the KRAS-SOS1 interface with small molecules prevents this nucleotide exchange, effectively locking KRAS in its inactive state regardless of the specific mutation present. This strategy aims to inhibit downstream oncogenic signaling and is currently being explored in clinical trials for various KRAS-driven malignancies (ClinicalTrials.gov: NCT04111458).

Other names
KRAS-SOS1 interactionKRAS:SOS1 complexSOS1-KRAS interfaceRAS-SOS interface
02

Mechanism of action

Inhibition of the protein-protein interaction between KRAS and SOS1, preventing the SOS1-mediated exchange of GDP for GTP on KRAS, thereby maintaining KRAS in an inactive state (PMID: 31439706).

03

Biological functions

Signal transductionCell proliferationGDP-GTP exchangeMAPK/ERK pathway activation
04

Disease associations

CancerPancreatic adenocarcinomaColorectal cancerNon-small cell lung cancer
05

Safety considerations

Gastrointestinal toxicity (diarrhea, vomiting)Compensatory feedback activation of upstream receptor tyrosine kinasesPotential impact on wild-type RAS signaling in healthy tissuesSkin rash
06

Interacting drugs

BI-3406

3 more in the full profile.

07

Biomarkers

KRAS mutation status (e.g., G12C, G12D, G12V)SOS1 expression levelsPhospho-ERK levelsDUSP6 mRNA expression

Beyond the preview

Go deeper on Kirsten rat sarcoma virus oncogene homolog (KRAS) - Son of Sevenless homolog 1 (SOS1) protein-protein interface (KRAS-SOS1 interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kirsten rat sarcoma virus oncogene homolog (KRAS) - Son of Sevenless homolog 1 (SOS1) protein-protein interface (KRAS-SOS1 interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call